Jasper Therapeutics (JSPR) Cash from Financing Activities (2020 - 2025)
Jasper Therapeutics (JSPR) posted quarterly Cash from Financing Activities of -$340000.0 for Q4 2025, down 198.55% year-over-year from $345000.0 in Q4 2024, and down 101.2% quarter-over-quarter from $28.4 million in Q3 2025.
Jasper Therapeutics (JSPR) Cash from Financing Activities (2020 - 2025) Analysis & Trends
Jasper Therapeutics' Cash from Financing Activities history runs 6 years deep, the most recent figure standing at -$340000.0 for Q4 2025.
- In Q4 2025, Cash from Financing Activities fell 198.55% year-over-year to -$340000.0; the TTM figure through Dec 2025 stood at $28.4 million (down 40.69% YoY), while the FY2025 annual figure was $34.2 million, down 28.55% from the prior year.
- Cash from Financing Activities for Q4 2025 stood at -$340000.0, down from $28.4 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $101.5 million in Q1 2023, with the low at -$909000.0 in Q4 2021.
- The 5-year median for Cash from Financing Activities is $20500.0 (2022), against an average of $15.4 million.
- Peak annual rise in Cash from Financing Activities reached 780753.85% in 2023, while the deepest fall reached 2446.15% in 2023.
- Jasper Therapeutics' Cash from Financing Activities stood at -$909000.0 in 2021, then surged by 103.08% to $28000.0 in 2022, then tumbled by 1067.86% to -$271000.0 in 2023, then surged by 227.31% to $345000.0 in 2024, then sank by 198.55% to -$340000.0 in 2025.
- Business Quant data shows JSPR's Cash from Financing Activities at -$340000.0 in Q4 2025, $28.4 million in Q3 2025, and $345000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 36.24 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 27.18 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | -273.15 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -16.65 Mn |
| 10 | Jasper Therapeutics | 20.06 Mn | 20.06 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -340,000.00 |
| Dec 31, 2025 | -340,000.00 |
| Sep 30, 2025 | 28.39 Mn |
| Sep 30, 2025 | 28.39 Mn |
| Dec 31, 2024 | 345,000.00 |
| Dec 31, 2024 | 345,000.00 |
| Sep 30, 2024 | 9,000.00 |
| Sep 30, 2024 | 9,000.00 |
| Jun 30, 2024 | 181,000.00 |
| Jun 30, 2024 | 181,000.00 |
| Mar 31, 2024 | 47.35 Mn |
| Mar 31, 2024 | 47.35 Mn |
| Dec 31, 2023 | -271,000.00 |
| Dec 31, 2023 | -271,000.00 |
| Sep 30, 2023 | 36,000.00 |
| Sep 30, 2023 | 36,000.00 |
| Jun 30, 2023 | -305,000.00 |
| Jun 30, 2023 | -305,000.00 |
| Mar 31, 2023 | 101.51 Mn |
| Mar 31, 2023 | 101.51 Mn |